diabetic peripheral atherosclerosis
Conditions
Interventions
Control group:placebo
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. According to Cardiovascular Disease and Risk Management in the Standards of Medical Care in Diabetes (2021 edition) published by American Diabetes Association (ADA), Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 edition) by Chinese Diabetes Society (CDS), and Guideline for Ultrasound Examination of Blood Vessels and Superficial Organs by Ultrasound Society of Chinese Medical Doctor Association, patients with (1) Definite diagnosis of T2DM; (2) Color doppler ultrasound of the carotid or lower extremity arteries suggested intima-media thickening (IMT >= 1mm) and/or atherosclerotic plaque (limited IMT >= 1.5mm). 2. According to Guiding Principles for New Drug Clinical Research of TCM and Guidelines for Prevention and Treatment of Diabetes in TCM by China Association of Chinese Medicine; 3. Aged 30 to 65 years; 4. Patients participate voluntarily and sign the Informed Consent Form; 5. When patients are screened, woman of childbearing age must have a negative urine pregnancy test and agree to use reliable contraception during this trial.
Exclusion criteria
Exclusion criteria: 1. Patients with calcified plaques or unstable plaques in lower extremity or carotid arteries, or arterial stenosis (vascular inner diameter stenosis >= 50%), or arterial occlusion; 2. Patients who have been diagnosed with coronary heart disease by coronary angiography, or whose electrocardiogram (ECG) and clinical manifestations suggest coronary heart disease, or who have had clear cardiovascular and cerebrovascular events, such as acute coronary syndrome and cerebral infarction; 3. Ankle-brachial index (ABI) 5.7 mmol/L; 5. Patients with abnormal liver and kidney function, such as the ratio of serum alanine aminotransferase (ALT) to aspartate aminotransferase (AST) higher than 1.5 times of the upper limit of normal value, creatinine (Cr) higher than the upper limit of normal value, estimated GFR (eGFR) <= 60 ml·min-1·(1.73m2)-1; 6. Patients with acute metabolic disorders such as diabetic ketoacidosis, or severe stress, occurred within 1 month before screening; 7. Patients with serious illnesses whose life expectancy does not exceed 2 years, or malignant tumor, or mental diseases. 8. Patients who are known to be allergic to the ingredients in SQXT formula or its preparations; 9. Having a history of alcoholism or drug abuse; 10. Women who are preparing for pregnancy, or pregnant, or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carotid artery intima media thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose;cholesterol;Glycated hemoglobin;Chinese version of diabetes management self-efficacy scale;vascular internal diameter of the bilateral carotid artery, anterior tibial artery, posterior tibial artery and dorsalis pedis artery;Ankle brachial index;end diastolic velocity of the bilateral carotid artery, anterior tibial artery, posterior tibial artery and dorsalis pedis artery;Triglycerides;peak systolic velocity of the bilateral carotid artery, anterior tibial artery, posterior tibial artery and dorsalis pedis artery;Brachial artery blood flow-mediated vasodilation;High density cholesterol;hyperechoic thickness of the arterial lumen wall of the bilateral carotid artery, anterior tibial artery, posterior tibial artery and dorsalis pedis artery;mean velocity of the bilateral carotid artery, anterior tibial artery, posterior tibial artery and dorsalis pedis artery;Quality of life scale for patients with Type 2 diabetes mellitus ; | — |
Countries
China
Contacts
Public ContactXie Hongyan
Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed